2 Day Molecular Biology for the Non-molecular Biologist Training Course: Elevate your Expertise in Pharmaceuticals Research, Development and Manufacturing (ONLINE EVENT: June 3-4, 2025)
DUBLIN--(BUSINESS WIRE)--May 20, 2025--
The 'Molecular Biology for the Non-molecular Biologist Training Course' training has been added to ResearchAndMarkets.com's offering.
Elevate your expertise in molecular biology to excel in pharmaceuticals research, development and manufacturing.
Molecular biology is not just a theoretical pursuit; it's a practical tool essential for understanding and manipulating the DNA, RNA and protein interactions that underpin drug discovery, development, and personalised medicine. This field's applications extend beyond the basic research, impacting biotechnology, microbiology and the pharmaceutical industry. As the demand for advanced molecular techniques grows, professionals must stay current with the latest breakthrough and regulatory requirements. This course will provider you with the knowledge and skills to excel in your role, whether you're involved in research, development, quality assurance, regulatory affairs, or manufacturing.
This course offers a comprehensive introduction to these concepts, equipping you with the necessary skills and insights to excel in your role and stay ahead in this dynamic field.
Key topics covered in this course:
Benefits of attending
Certifications:
Who Should Attend:
Key Topics Covered:
Day 1
Principles of molecular biology I
Principles of molecular biology II
Practical skills in molecular biology
Molecular biology, disease diagnosis, personalised medicine and genetic screening
Molecular biology and forensics
Day 2
Recent breakthroughs in molecular biology
Molecular biology in medicine
Molecular biology and biotechnology
Application of molecular biology discussion
For more information about this training visit https://www.researchandmarkets.com/r/c4yej6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250520055724/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected] E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: BIOTECHNOLOGY GENETICS HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2025.
PUB: 05/20/2025 08:41 AM/DISC: 05/20/2025 08:40 AM
http://www.businesswire.com/news/home/20250520055724/en
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Digitate Advances Agentic AI Platform to Accelerate Enterprises Towards Autonomous, Ticketless IT and Business Operations
New release launches purpose-built AI agents for IT and SREs as well as AI Assistants for CIOs to tackle complex enterprise tasks SANTA CLARA, Calif., June 04, 2025--(BUSINESS WIRE)--Digitate, a leading global SaaS provider of AIOps solutions, today announced the launch of its latest release designed to help IT and business leaders materialize their vision of autonomous enterprise and ticketless operations. Built on ignio™ – a powerful Agentic AI platform for IT and business operations, the new release introduces a suite of AI agents capable of handling even the most complex IT and business tasks with speed and precision, supercharging employee productivity and elevating business resiliency to new heights. "The complexity of today's enterprises needs intelligent agents that can understand, decide, and act with autonomy," said Rahul Kelkar, Chief Product Officer of Digitate. "With ignio, we envisioned a future of autonomous enterprises and pioneered the fusion of AI and automation from our very first release 10 years ago. Each subsequent release has empowered our customers to move away from reactive IT and step confidently into a world of proactive, self-driving ticketless operations. Our new Agentic AI platform and AI agents mark the next phase in this evolution, empowering CIOs, SRE teams, IT, and business operations to harness the power of ignio's agentic platform and AI agents to accelerate their autonomous enterprise journey." Digitate's Agentic AI framework reimagines enterprise AI as a system of autonomous, goal-oriented, and context-aware agents. These agents operate independently or collaboratively, continuously learning from their environment, understanding intent, and making informed decisions – elevating enterprise IT from rule-based automation to intelligent autonomy. Digitate's initial AI agents will address the following specific IT functions and personas: AI Agent for IT Event Management: Designed to autonomously ingest, correlate, and prioritize millions of IT events in real time, this agent cuts through noise, identifies patterns, and flags actionable insights—transforming event chaos into clear operational intelligence. AI Agent for Incident Resolution: Built to intelligently resolve incidents across hybrid environments, this agent combines contextual understanding with autonomous execution. It handles known issues and adapts to emerging ones—significantly reducing mean time to resolution (MTTR). AI Agent for SRE: Tailored for Site Reliability Engineering (SRE) teams, this agent enhances observability and tracking across the enterprise tech stack, enabling hands-on support and proactive reliability management. AI Assist for CIO: Engineered for CIOs who require unified, high-level data from across the enterprise to make informed decisions about strategy, governance, business continuity, and cost optimization. Starting today, Digitate will offer early previews of the new AI agents, with general availability to follow in the coming weeks. The AI agent for IT event management is now available for a free trial on Azure Monitor via Microsoft Azure Marketplace. To learn more about Digitate's new Agentic AI platform and AI agents, visit About Digitate Digitate builds AI technologies to power the autonomous enterprise. Our agentic AI platform – ignio™ – combines unified observability, AI-powered insights, and closed-loop automation to help enterprises across industries operate smarter, faster, and with greater resilience. Built on an agentic AI architecture, ignio enables proactive and predictive IT and business operations. Trusted by leading global enterprises and innovators, ignio accelerates innovation and maximizes business outcomes. Learn more at and follow Digitate on X and LinkedIn. View source version on Contacts Mark Button10Fold for DigitateTel: 408-310-2168digitate@ Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
eClinical Solutions to Lead Industry Discussions on Modernizing Clinical Trials at DIA 2025 and Series of Company Events This Summer
Global eClinical Connect events kick off this week, leading up to annual ENGAGE conference in the fall, as company continues to build innovative avenues to empower life sciences leaders BOSTON, June 04, 2025--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and services, today announced its participation in several June events, including the DIA 2025 Global Annual Meeting, a leading life sciences event that brings together industry professionals to drive large-scale collaboration and transformation in the sector. With the company's commitment to supporting biopharma researchers in driving tomorrow's breakthroughs, eClinical is also hosting the eClinical Connect event series, including two events in Europe, creating additional global forums for industry experts to share insights and actionable strategies to tackle today's most pressing issues in the life sciences. DIA 2025 Global Annual Meeting Following years of industry and regulatory efforts to ensure inclusive and representative trials, including Diversity Action Plans, leaders are collaborating to make tangible progress on initiatives promoting clinical trial diversity. To support these efforts, eClinical Solutions will host a panel at DIA (June 15-19 in Washington, DC) titled "Techquity in Digital Trials: Tech, Data, and Operationalizing Equity in Clinical Research," which will explore how biopharma can leverage data foundations and technological advancements - including artificial intelligence (AI) and machine learning (ML) - to improve access and representation in clinical trials. eClinical Solutions' Katrina Rice, Chief Delivery Officer of Biometrics Services, will chair the panel and be joined by industry authorities including Patrick Gee, Patient Advocate, Founder and Chief Executive Hope Dealer at iAdvocate, Inc., Nicole Ward, Senior Product Manager, Business Insights and Technology at Bristol Myers Squibb, and Del Smith, CEO and Co-founder at Acclinate. The discussion will focus on critical areas where technology and analytics can help facilitate health equity advancement, outline concrete use cases where technology and data can support equitable clinical research, and detail non-technical success factors needed to wholly support data-driven technology. The conversation will take place June 18 between 1:45 pm - 2:45 pm ET. eClinical Connect In addition to its presence at this premier industry conference, the company will host three complimentary, global eClinical Connect events this month, which feature timely and informative panel discussions: eClinical Connect in Newton, Massachusetts, USA (June 4): The first event will focus on considerations for adopting risk-based approaches, which continue to be top of mind as regulatory demands increase and clinical trials become more complex. eClinical Connect in Mainz, Germany (June 10): The first European installment will include half-day presentations, providing attendees with insight on future-ready data strategies, elluminate Clinical Data Cloud® adoption case studies presented by prominent Top 50 biopharma, and the eClinical Solutions vision and elluminate roadmap – including use cases for enabling clinical teams with robust data transformation tools. eClinical Connect in Paris, France (June 12): Later the same week in Europe, the Paris Connect's sessions and speakers will cover AI strategies, holistic approaches to risk-based quality management (RBQM), expanding clinical data platform use cases across an organization, and a CRO's experience streamlining data cleaning with a centralized data workbench. "With a massive technology reinvention upon us thanks to the growing power and priority level of AI, it was important for us to supplement distinguished industry events like DIA with additional forums for collaboration with our clients and other life sciences stakeholders to discuss the most effective clinical trial strategies and approaches," said Raj Indupuri, Co-founder and CEO at eClinical Solutions. "During this unprecedented time, we must carefully examine how to most effectively harness AI tools safely with trust to improve key industry pain points. We are proud to convene top minds in life sciences at our eClinical Connect events to not only discuss unlocking AI's potential across the clinical data lifecycle, but also dive into other pertinent topics including holistic RBQM and risk-based approaches to optimize cycle times and future-proof trials, ultimately delivering innovative therapies to patients faster." eClinical Solutions has also revealed details into this year's ENGAGE Annual Conference, which will be held October 29-30 in Philadelphia, Pennsylvania. The event will provide executives the opportunity to explore the latest advancements in AI-driven innovation, insight into risk-based strategies to optimize decision-making, and tactical ways teams can reduce cycle times and improve efficiency. To learn more about these events, including how you can register to attend, visit the eClinical Solutions website: About eClinical Solutions eClinical Solutions' industry-leading data & analytics platform, elluminate®, and biometrics services experts help biopharma researchers at large, mid-size, and emerging life sciences organizations manage trial complexity in less time and with fewer resources. Clients get accurate and timely data insights for better decision-making – enabling them to reduce cycle times, improve productivity, easily scale, and develop tomorrow's breakthroughs with today's resources. eClinical is a privately-held, purpose-driven company with a global workforce and winner of the 2025 Top Workplaces Culture Excellence Award, 2024 Top Workplaces USA Award, and Great Place To Work® India Certification™. Learn more at and follow eClinical Solutions on LinkedIn. View source version on Contacts Olivia MannioneClinical@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Over the Counter (OTC) Drugs Market Report 2025: Opportunities, Growth Drivers, Industry Trend Analysis, and Forecasts to 2034
Driven by self-medication trends, health-conscious consumers, and innovative formulations, the OTC drugs market thrives on the widespread availability of non-prescription drugs. Key segments include cold remedies and tablets, heavily favored for convenience. The U.S. market alone is expected to expand at a 4.8% CAGR, fueled by strong R&D and self-care trends. Over the Counter (OTC) Drugs Market Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Over the Counter (OTC) Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to Over the Counter (OTC) Drugs Market was valued at USD 180 Billion in 2024, and is projected to reach USD 302.3 Billion by 2034, rising at a CAGR of 5.40%, driven largely by a rising consumer preference for self-medication and increasing demand for accessible healthcare solutions. As consumers become more health-conscious and proactive in managing minor ailments, OTC drugs are quickly emerging as a go-to solution for quick relief and cost-effective treatment options. The widespread availability of OTC products in pharmacies, supermarkets, online platforms, and convenience stores is making it easier for consumers to access essential medications without a prescription. In addition, ongoing advancements in drug formulations, such as fast-dissolving tablets and flavored syrups, are enhancing user convenience and compliance, fueling market growth even further. Regulatory bodies across the globe are also playing a crucial role by ensuring stringent quality checks and guidelines, which boost consumer confidence in using OTC medications for everyday health concerns. As healthcare costs continue to rise, many individuals are opting for OTC options to manage common conditions like pain, colds, digestive issues, and skin irritations without the need for physician visits, thereby contributing to overall market expansion. Furthermore, an aging population seeking easy and affordable solutions for recurring issues like joint pain, digestive discomfort, and sleep disorders is supporting long-term demand for OTC products. The growing trend toward preventive healthcare and wellness supplements is also influencing consumer purchasing behavior, with many people adopting vitamins, minerals, and herbal supplements as part of their daily routines to maintain health and drugs, which do not require a doctor's prescription, are carefully regulated by health authorities to ensure their safety, efficacy, and quality. These medications are available in diverse forms, such as tablets, ointments, sprays, and solutions, offering users convenient options for managing common health issues at home. The market is segmented into various categories, including cold and cough remedies, vitamins and supplements, digestive aids, skin treatments, pain relievers, sleeping aids, and others. Among these, cold and cough remedies generated USD 45.2 billion in 2024, as the rising incidence of respiratory illnesses like colds and flu, particularly during seasonal transitions, drives demand for quick-relief products such as decongestants and cough looking at product formulation, tablets dominated the OTC market with USD 85.9 billion in 2024, as they remain the preferred choice due to precise dosing, convenience, and ease of use for treating conditions such as pain, respiratory issues, and other acute ailments. The consistent launch of new tablet-based OTC products continues to boost their market regional analysis, the U.S. OTC Drugs Market accounted for USD 42.4 billion in 2024 and is anticipated to grow at a 4.8% CAGR through 2034. The country's robust pharmaceutical landscape, significant R&D investments, and rising consumer inclination toward self-care are propelling market growth alongside growing awareness around early treatment and preventive healthcare Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis The companies profiled in this Over the Counter (OTC) Drugs market report include: Abbott Alkem Laboratories Aytu Biopharma (Aytu Consumer Health) Bayer AG Cipla Dr. Reddy's Laboratories GlaxoSmithKline Plc Glenmark Pharmaceuticals Haleon Johnson & Johnson Services Perrigo Company Pfizer Piramal Enterprises Reckitt Benckiser Group Sanofi Sun Pharmaceuticals Teva Pharmaceutical Industries The Blackstone Group (Alinamin Pharmaceutical) Viatris Key Attributes: Report Attribute Details No. of Pages 130 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $180 Billion Forecasted Market Value (USD) by 2034 $302.3 Billion Compound Annual Growth Rate 5.4% Regions Covered Global Key Topics Covered: Chapter 1 Methodology and ScopeChapter 2 Executive Summary2.1 Industry 360 degree synopsisChapter 3 Industry Insights3.1 Industry ecosystem analysis3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Growing consumer awareness for self-medication and disease management3.2.1.2 High cost of prescription drugs leading to shift towards OTC drugs3.2.1.3 Favorable regulatory support for OTC drug approvals3.2.1.4 Expanding product accessibility3.2.2 Industry pitfalls and challenges3.2.2.1 Concern towards misuse or drug abuse3.2.2.2 Potential side effects and interactions due to medication3.3 Growth potential analysis3.4 Regulatory landscape3.5 Prescription to nonprescription switch list3.6 Future market trends3.7 Porter's analysis3.8 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company matrix analysis4.3 Company market share analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Strategy dashboardChapter 5 Market Estimates and Forecast, by Drug Category, 2021-2034 ($ Mn)5.1 Key trends5.2 Cold and cough remedies5.3 Vitamins and supplements5.4 Digestive and intestinal remedies5.5 Skin treatment5.6 Analgesics5.7 Sleeping aids5.8 Other drug categoriesChapter 6 Market Estimates and Forecast, by Formulation Type, 2021-2034 ($ Mn)6.1 Key trends6.2 Tablets6.3 Liquids6.4 Ointments6.5 SpraysChapter 7 Market Estimates and Forecast, by Distribution Channel, 2021-2034 ($ Mn)7.1 Key trends7.2 Online channels7.3 Offline channels7.3.1 Hospital pharmacies7.3.2 Retail pharmacies7.3.3 Other offline channelsChapter 8 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)8.1 Key trends8.2 North America8.2.1 U.S.8.2.2 Canada8.3 Europe8.3.1 Germany8.3.2 UK8.3.3 France8.3.4 Spain8.3.5 Italy8.3.6 Netherlands8.4 Asia Pacific8.4.1 China8.4.2 India8.4.3 Japan8.4.4 Australia8.4.5 South Korea8.5 Latin America8.5.1 Brazil8.5.2 Mexico8.5.3 Argentina8.6 Middle East and Africa8.6.1 South Africa8.6.2 Saudi Arabia8.6.3 UAEChapter 9 Company Profiles9.1 Abbott9.2 Alkem Laboratories9.3 Aytu Biopharma (Aytu Consumer Health)9.4 Bayer AG9.5 Cipla9.6 Dr. Reddy's Laboratories9.7 GlaxoSmithKline Plc9.8 Glenmark Pharmaceuticals9.9 Haleon9.10 Johnson & Johnson Services9.11 Perrigo Company9.12 Pfizer9.13 Piramal Enterprises9.14 Reckitt Benckiser Group9.15 Sanofi9.16 Sun Pharmaceuticals9.17 Teva Pharmaceutical Industries9.18 The Blackstone Group (Alinamin Pharmaceutical)9.19 ViatrisCompanies Featured The companies profiled in this Over the Counter (OTC) Drugs market report include: Abbott Alkem Laboratories Aytu Biopharma (Aytu Consumer Health) Bayer AG Cipla Dr. Reddy's Laboratories GlaxoSmithKline Plc Glenmark Pharmaceuticals Haleon Johnson & Johnson Services Perrigo Company Pfizer Piramal Enterprises Reckitt Benckiser Group Sanofi Sun Pharmaceuticals Teva Pharmaceutical Industries The Blackstone Group (Alinamin Pharmaceutical) Viatris For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Over the Counter (OTC) Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
